Defining dose-limiting toxicity for phase 1 trials of molecularly targeted agents: Results of a DLT-TARGETT international survey

European Journal of Cancer

Volumn 50, Issue 12, 2014, Pages 2050-2056

  Paoletti, Xavier ^a   Le Tourneau, Christophe ^a   Verweij, Jaap ^b   Siu, Lillian L ^c   Seymour, Lesley ^d   Postel Vinay, Sophie ^i,j   Collette, Laurence ^e   Rizzo, Elisa ^e   Ivy, Percy ^f   Olmos, David ^g   Massard, Christophe ^i,j   Lacombe, Denis ^e   Kaye, Stan B ^h   Soria, Jean Charles ^i,j  

^a INSERM U900   (France)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c PRINCESS MARGARET HOSPITAL   (Canada)

^d QUEEN S UNIVERSITY   (Canada)

^e EORTC DATA CENTER   (Belgium)

^f NATIONAL CANCER INSTITUTE   (United States)

^g Centro Nacional de Investigaciones Oncológicas   (Spain)

^h ROYAL MARSDEN HOSPITAL   (United Kingdom)

ⁱ INSTITUT GUSTAVE ROUSSY   (France)

^j UNIVERSITÉ PARIS SACLAY   (France)

more..

Author keywords

Assessment period; Dose intensity; Dose limiting toxicity; Experts; Phase 1; Recommended phase 2 dose

Indexed keywords

MOLECULAR THERAPY AGENT;

ARTICLE; CANADA; DOSE LIMITING TOXICITY; DRUG DOSE; FRANCE; HUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; PRIORITY JOURNAL; PROFESSIONAL PRACTICE; QUESTIONNAIRE; TOXICITY TESTING; TOXICOLOGICAL PARAMETERS; UNITED KINGDOM;

ASSESSMENT PERIOD; DOSE INTENSITY; DOSE-LIMITING TOXICITY; EXPERTS; PHASE 1; RECOMMENDED PHASE 2 DOSE;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS, PHASE I AS TOPIC; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; RESEARCH DESIGN;

EID: 84904071224     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2014.04.030     Document Type: Article

References (15)

1. L.R. Molife, S. Alam, D. Olmos, M. Puglisi, K. Shah, and R. Fehrmann et al. Defining the risk of toxicity in phase I oncology trials of novel molecularly targeted agents: a single centre experience Ann Oncol 23 8 2012 1968 1973
2. S. Postel-Vinay, C. Gomez-Roca, L.R. Molife, B. Anghan, A. Levy, and I. Judson et al. Phase I trials of molecularly targeted agents: should we pay more attention to late toxicities? J Clin Oncol 29 13 2011 1728 1735
3. J. Verweij, M.L. Disis, and S.A. Cannistra Phase I studies of drug combinations J Clin Oncol 28 30 2010 4545 4546
4. J.Y. Blay, and P. Rutkowski Adherence to imatinib therapy in patients with gastrointestinal stromal tumors Cancer Treat Rev 40 2 2014 242 247
5. A. Wigertz, J. Ahlgren, M. Holmqvist, T. Fornander, J. Adolfsson, and H. Lindman et al. Adherence and discontinuation of adjuvant hormonal therapy in breast cancer patients: a population-based study Breast Cancer Res Treat 133 1 2012 367 373
6. C. Le Tourneau, A.R. Razak, H.K. Gan, S. Pop, V. Dieras, and P. Tresca et al. Heterogeneity in the definition of dose-limiting toxicity in phase I cancer clinical trials of molecularly targeted agents: a review of the literature Eur J Cancer 47 10 2011 1468 1475
7. E.A. Eisenhauer, P. Therasse, J. Bogaerts, L.H. Schwartz, D. Sargent, and R. Ford et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) Eur J Cancer 45 2 2009 228 247
8. C.J. Punt, M. Buyse, C.H. Kohne, P. Hohenberger, R. Labianca, and H.J. Schmoll et al. Endpoints in adjuvant treatment trials: a systematic review of the literature in colon cancer and proposed definitions for future trials J Natl Cancer Inst 99 13 2007 998 1003
9. A. Hollebecque, S. Postel-Vinay, J. Verweij, G.D. Demetri, K. Flaherty, and P. Bedard et al. Modifying phase I methodology to facilitate enrolment of molecularly selected patients Eur J Cancer 49 7 2012 1515 1520
10. D.A. Asch, M.K. Jedrziewski, and N.A. Christakis Response rates to mail surveys published in medical journals J Clin Epidemiol 50 10 1997 1129 1136
11. C.A. Bellera, M. Pulido, S. Gourgou, L. Collette, A. Doussau, and A. Kramar et al. Protocol of the Definition for the Assessment of Time-to-event Endpoints in CANcer trials (DATECAN) project: formal consensus method for the development of guidelines for standardised time-to-event endpoints' definitions in cancer clinical trials Eur J Cancer 49 4 2013 769 781
12. C.M. Booth, A.H. Calvert, G. Giaccone, M.W. Lobbezoo, L.K. Seymour, and E.A. Eisenhauer Endpoints and other considerations in phase I studies of targeted anticancer therapy: recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies (MDICT) Eur J Cancer 44 1 2008 19 24
13. A. Iasonos, and J. O'Quigley Design considerations for dose-expansion cohorts in phase I trials J Clin Oncol 31 31 2013 4014 4021
14. A. Manji, I. Brana, E. Amir, G. Tomlinson, I.F. Tannock, and P.L. Bedard et al. Evolution of clinical trial design in early drug development: systematic review of expansion cohort use in single-agent phase I cancer trials J Clin Oncol 31 33 2013 4260 4267
15. J.W. Moroney, M.P. Schlumbrecht, T. Helgason, R.L. Coleman, S. Moulder, and A. Naing et al. A phase I trial of liposomal doxorubicin, bevacizumab, and temsirolimus in patients with advanced gynecologic and breast malignancies Clin Cancer Res 17 21 2012 6840 6846